Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias
Author Information
Author(s): A.A. Keeling, A.T.M. Vaughan, R.P. Beaney
Primary Institution: Department of Immunology, University of Birmingham
Hypothesis
Can Yttrium-90 chelated by EDTMP improve treatment outcomes for leukaemia?
Conclusion
Yttrium-90-EDTMP shows high uptake in bone and rapid clearance from soft tissues, making it a promising treatment for leukaemia.
Supporting Evidence
- Yttrium-90-EDTMP achieved a high uptake in bone.
- The biological half-life of Yttrium-90 in bone was greater than 72 hours.
- Repeated chelation therapy with DTPA reduced the dose needed by 50%.
- EDTMP was considered the reagent of choice for delivering Yttrium-90 to bone.
Takeaway
This study found that a special treatment using Yttrium-90 can help target leukaemia cells in the bones while being safer for other body parts.
Methodology
The study involved biodistribution studies in BALB/c mice to assess the uptake of Yttrium-90-EDTMP in bone and soft tissues.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Male BALB/c mice weighing between 18 and 28 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website